|
9,687
|
| 102209 |
Angiotensin A
|
|
increases_quantity of
|
Alamandine
|
|
| 102338 |
ACE2
|
|
increases_quantity of
|
Alamandine
|
|
| 102339 |
ACE2
|
|
decreases_quantity of
|
Angiotensin A
|
|
|
23446738
|
Cardiovascular disease
|
|
9,698
|
| 102346 |
Angiotensin (1-7)
|
|
increases_quantity of
|
Alamandine
|
|
|
23446738
|
Cardiovascular disease
|
|
11,676
|
| 116055 |
TMPRSS2
|
|
affects_activity of
|
ACE2
|
via proteolytic processing to improve SARS-S-driven transduction
|
| 117211 |
ADAM17
|
|
decreases_quantity of
|
ACE2
|
via proteolytic processing
|
| 117212 |
ADAM17
|
|
affects_activity of
|
TMPRSS2
|
|
| 117762 |
ADAM17
|
|
increases_quantity of
|
ACE2, soluble
|
|
| 119246 |
ACE2
|
|
increases_quantity of
|
ACE2, soluble
|
via proteolytic activity of ADAM17
|
| 136192 |
TMPRSS2
|
|
increases_quantity of
|
ACE2, soluble
|
via proteolytic processing to improve SARS-S-driven transduction
|
|
24227843
|
Immunological
SARS-CoV infection
|
|
11,684
|
| 116070 |
sex, male
|
|
increases_activity of
|
ACE2
|
in cardiac tissue; compared to female
|
| 117240 |
sex, male
|
|
increases_activity of
|
ACE
|
in cardiac tissue; compared to female
|
|
|
Cardiovascular disease
COVID-19
|
|
11,717
|
| 116411 |
AGTR1
|
|
increases_activity of
|
inflammatory response
|
|
| 116413 |
AGTR1
|
|
increases_activity of
|
response to oxidative stress
|
|
| 116414 |
AGTR2
|
|
increases_activity of
|
vasodilation
|
|
|
30404071
|
Diabetes mellitus, type II
Insulin resistance
|
|
11,748
|
| 116372 |
Angiotensin IV
|
|
increases_activity of
|
AGTR1
|
|
| 116378 |
Angiotensin (1-7)
|
|
increases_activity of
|
AGTR2
|
but with lower affinity than ANG II
|
| 116379 |
Angiotensin II
|
|
increases_activity of
|
AGTR2
|
with higher affinity than Angiotensin (1-7)
|
| 116392 |
ADAM17
|
|
increases_quantity of
|
ACE2, soluble
|
via proteolysis
|
| 116398 |
PREP
|
|
increases_quantity of
|
Angiotensin (1-7)
|
|
|
32333398
|
COVID-19
|
|
11,751
|
| 116385 |
MME
|
|
decreases_quantity of
|
Angiotensin I
|
|
| 116894 |
Angiotensin I
|
|
increases_quantity of
|
Angiotensin (1-7)
|
via catalytic action of MME (NEP)
|
| 116895 |
Angiotensin (1-9)
|
|
increases_quantity of
|
Angiotensin (1-7)
|
via catalytic action of MME (NEP)
|
| 116896 |
MME
|
|
increases_quantity of
|
Angiotensin (1-7)
|
|
| 116897 |
MME
|
|
decreases_quantity of
|
Angiotensin (1-9)
|
|
|
15283675
|
Endocrine
|
|
11,776
|
| 116576 |
REN
|
|
decreases_quantity of
|
Angiotensinogen
|
|
| 116577 |
REN
|
|
increases_quantity of
|
Angiotensin I
|
|
| 116578 |
Angiotensin II
|
|
increases_activity of
|
AGTR1
|
|
| 116579 |
Angiotensin II
|
|
increases_activity of
|
AGTR2
|
|
| 116586 |
PREP
|
|
decreases_quantity of
|
Angiotensin I
|
|
| 116587 |
PREP
|
|
increases_quantity of
|
Angiotensin (1-7)
|
|
|
23463883
|
Diabetes mellitus, type II
Insulin resistance
Cardiovascular disease
|
|
11,823
|
| 116810 |
Angiotensin II
|
|
increases_quantity of
|
Angiotensin (1-7)
|
via the action of ACE2
|
|
11815627
|
Metabolic
|
|
11,827
|
| 116824 |
SARS-CoV-2 S protein
|
|
interacts (colocalizes) with
|
ACE2
|
|
| 116872 |
TMPRSS2
|
|
increases_activity of
|
SARS-CoV-2 S protein
|
|
| 116877 |
Camostat mesilate
|
|
decreases_activity of
|
TMPRSS2
|
in lung cells
|
|
32142651
|
COVID-19
|
|
11,830
|
| 116886 |
SARS-CoV S protein
|
|
increases_quantity of
|
Angiotensin II
|
in the lung
|
| 116888 |
AGTR1
|
|
affects_activity of
|
pulmonary edema
|
in SARS-CoV S protein-treated mice
|
| 119082 |
SARS-CoV infection
|
|
decreases_quantity of
|
ACE2
|
in the lung
|
|
16007097
|
SARS-CoV infection
|
|
11,833
|
| 116986 |
COVID-19
|
|
increases_quantity of
|
Angiotensin II
|
in blood plasma
|
|
32048163
|
COVID-19
|
|
11,837
|
| 116863 |
ACE
|
|
decreases_quantity of
|
Angiotensin I
|
|
| 116866 |
ACE
|
|
increases_quantity of
|
Angiotensin II
|
|
| 116867 |
Angiotensin I
|
|
increases_quantity of
|
Angiotensin II
|
via the catalytic activity of ACE
|
| 116868 |
Angiotensin I
|
|
increases_quantity of
|
Angiotensin (1-9)
|
via the catalytic activity of ACE2
|
| 116869 |
ACE2
|
|
decreases_quantity of
|
Angiotensin I
|
|
| 116870 |
ACE2
|
|
increases_quantity of
|
Angiotensin (1-9)
|
|
| 116873 |
ACE
|
|
decreases_quantity of
|
Angiotensin (1-9)
|
|
| 116874 |
ACE
|
|
increases_quantity of
|
Angiotensin (1-7)
|
|
| 116875 |
ACE
|
|
increases_quantity of
|
Angiotensin (1-5)
|
|
| 116876 |
ACE
|
|
decreases_quantity of
|
Angiotensin (1-7)
|
|
| 116883 |
Angiotensin (1-7)
|
|
increases_quantity of
|
Angiotensin (1-5)
|
|
| 116884 |
Angiotensin (1-9)
|
|
increases_quantity of
|
Angiotensin (1-7)
|
|
|
10969042
|
Endocrine
|
|
11,842
|
| 116926 |
PRCP
|
|
decreases_quantity of
|
Angiotensin II
|
in kidney ; at acidic pH
|
| 116927 |
PRCP
|
|
increases_quantity of
|
Angiotensin (1-7)
|
in kidney ; at acidic pH
|
| 116928 |
ACE2
|
|
increases_quantity of
|
Angiotensin (1-7)
|
in kidney ; at neutral to basic pH
|
|
23392115
|
Endocrine
|
|
11,844
|
| 116935 |
THOP1
|
|
decreases_quantity of
|
Angiotensin I
|
in hippocampus
|
| 116936 |
THOP1
|
|
increases_quantity of
|
Angiotensin (1-7)
|
in hippocampus
|
| 116937 |
Angiotensin I
|
|
increases_quantity of
|
Angiotensin (1-7)
|
in hippocampus; via the catalytic action of THOP1
|
|
24041943
|
Neurological
|
|
11,899
|
| 117136 |
ACE2, soluble
|
|
increases_quantity of
|
Angiotensin (1-7)
|
in cerebrospinal fluid
|
| 117156 |
hypertension
|
|
increases_activity of
|
ACE2, soluble
|
in cerebrospinal fluid
|
| 117157 |
ACE2, soluble
|
|
decreases_quantity of
|
Angiotensin II
|
in cerebrospinal fluid
|
| 117239 |
AGTR1
|
|
increases_activity of
|
ADAM17
|
in cerebrospinal fluid; during the development of DOCA-salt hypertension
|
|
28512108
|
Neurological
SARS-CoV infection
|
|
11,902
|
| 117160 |
AGTR1
|
|
increases_activity of
|
ADAM17
|
in the hypothalamus ; during DOCA-salt hypertension
|
|
28512108
|
Neurological
|
|
11,908
|
| 117213 |
Angiotensin (1-7)
|
|
increases_activity of
|
AGTR2
|
if candesartan is coadministered
|
|
15767466
|
Cardiovascular disease
|
|
11,918
|
| 117242 |
Angiotensin (1-5)
|
|
increases_activity of
|
MAS1
|
in atrium
|
|
27660028
|
Cardiovascular disease
|
|
11,919
|
| 117249 |
Angiotensin (1-9)
|
|
increases_activity of
|
AGTR2
|
in cardiomyocytes
|
|
30048754
|
Cardiovascular disease
|
|
11,920
|
| 117252 |
Angiotensin II
|
|
increases_quantity of
|
Angiotensin A
|
|
| 117253 |
Angiotensin A
|
|
increases_activity of
|
AGTR1
|
|
| 117254 |
Angiotensin A
|
|
increases_activity of
|
AGTR2
|
|
|
17138938
|
Cardiovascular disease
|
|
11,921
|
| 117256 |
ENPEP
|
|
decreases_quantity of
|
Angiotensin II
|
in hypothalamus
|
| 117262 |
ENPEP
|
|
increases_quantity of
|
Angiotensin III
|
in hypothalamus
|
| 117263 |
ANPEP
|
|
decreases_quantity of
|
Angiotensin III
|
in hypothalamus
|
| 117264 |
ANPEP
|
|
increases_quantity of
|
Angiotensin IV
|
in hypothalamus
|
| 119255 |
Angiotensin II
|
|
increases_quantity of
|
Angiotensin III
|
in hypothalamus
|
| 119257 |
Angiotensin III
|
|
increases_quantity of
|
Angiotensin IV
|
in hypothalamus
|
|
8876246
|
Cardiovascular disease
|
|
11,922
|
| 117257 |
Angiotensin (1-7)
|
|
increases_activity of
|
MAS1
|
in LPS plus IFNG-stimulated macrophages
|
| 117268 |
Alamandine
|
|
increases_activity of
|
MRGPRD
|
in LPS plus IFNG-stimulated macrophages
|
| 117281 |
MRGPRD
|
|
decreases_activity of
|
inflammatory response
|
in LPS plus IFNG-stimulated macrophages
|
| 117282 |
MAS1
|
|
decreases_activity of
|
inflammatory response
|
in LPS plus IFNG-stimulated macrophages
|
|
30918468
|
Lung disease
|
|
11,923
|
| 117258 |
aging
|
|
increases_quantity of
|
ACE
|
in renal cortex
|
| 117259 |
aging
|
|
decreases_quantity of
|
ACE2
|
in renal cortex
|
|
20689271
|
Endocrine
|
|
11,924
|
| 117260 |
AGTR1
|
|
increases_activity of
|
ADAM17
|
in myocardium
|
|
24332999
|
Endocrine
|
|
11,926
|
| 117293 |
CMA1
|
|
decreases_quantity of
|
Angiotensin (1-12)
|
in heart
|
| 117294 |
CMA1
|
|
increases_quantity of
|
Angiotensin II
|
in heart
|
|
27465904
|
Cardiovascular disease
|
|
11,928
|
| 117302 |
Angiotensin (1-7)
|
|
increases_activity of
|
MAS1
|
in HEK293 cells
|
| 117307 |
Angiotensin (1-7)
|
|
increases_activity of
|
MRGPRD
|
in HEK293 cells
|
|
27217404
|
Cardiovascular disease
|
|
11,933
|
| 117310 |
Angiotensin III
|
|
interacts (colocalizes) with
|
AGTR1
|
in HEK293 cells
|
| 117313 |
Angiotensin III
|
|
interacts (colocalizes) with
|
AGTR2
|
in HEK293 cells
|
|
21542804
|
Cardiovascular disease
|
|
11,934
|
| 117316 |
MAS1
|
|
interacts (colocalizes) with
|
AGTR1
|
|
| 117333 |
MAS1
|
|
is_part_of
|
AGTR1-MAS1 complex
|
in HEK293 cells
|
| 117334 |
AGTR1
|
|
is_part_of
|
AGTR1-MAS1 complex
|
in HEK293 cells
|
| 117335 |
AGTR1-MAS1 complex
|
|
decreases_activity of
|
AGTR1
|
|
|
15809376
|
Cardiovascular disease
|
|
11,935
|
| 117359 |
Angiotensin (1-7)
|
|
decreases_activity of
|
AGTR1
|
|
|
29928987
|
Cardiovascular disease
|
CIDeRplus